Therapeutics developer Lead Pharmaceutical (Oss, Netherlands) and French medicinal chemistry and custom synthesis company Oxeltis, have been awarded an €800K ($842K) grant from EUREKA Eurostars for a three year project aimed at developing a first-in-class small molecule therapy for diffuse large B-cell lymphoma (DLBCL). Click to read more.
Dutch firm Lead Pharma and French company Oxeltis have been awarded an €800K grant from the 37-nation EUREKA intergovernmental network’s Euro.
Grant will fund three-year EPIGENEXT joint project aimed at developing first-in-class therapy for diffuse large B-cell lymphoma Oss, the Netherlands and Montpellier, France, June 8, 2022 – Lead Pharma, a privately held pharmaceutical company designing and developing innovative therapies for the treatment of immune-.